Irradiation of platelet concentrates is required to prevent graft-versus-host disease and this needs to follow national guidelines.
Platelet transfusion is contra-indicated in heparin-induced thrombocytopenia, thrombotic thrombocytopenic purpura and the haemolytic uraemic syndrome.
Recipients who are refractory to platelet transfusions
Failure to achieve a satisfactory response to platelet transfusion (refractoriness) occurs in up to half of those receiving prophylactic transfusions. This is defined by the poor increment in platelet count rather than on clinical grounds. Patients who remain refractory for immunological reasons, often receive prophylactic transfusions with HLA-matched or crossmatch-compatible platelets. Satisfactory increments are frequently obtained by these approaches but their effectiveness in reducing severe bleeding deserves more detailed evaluation. So does the relative effectiveness of HLA-matching compared to platelet crossmatching, and whether patients who remain refractory despite these measures should only be transfused therapeutically.
Quality control of platelet preparations
Further quality control measures should become routine in addition to those already undertaken and should include more 
Conclusion
The overall conclusion is that platelet transfusion is a well established clinical procedure but it can never be entirely safe and must be given only where there is clear clinical justification. Nevertheless the precise indications for its use and the optimal specification of the product still need to be defined. These goals will be achieved only by a combination of prospective randomised trials with the information that will come from the use of clearly defined protocols, and their efficient audit.
M Contreras
Royal College of Physicians of Edinburgh, Edinburgh, UK observed frequency, and the emergence of an apparently distinct clinical profile of affected individuals, the co-existence of these two disorders appears to be more than simply fortuitous. If validated, this association would broaden the range of autoimmune disorders known to complicate the course of patients with myelodysplastic disorders [2] [3] [4] and may provide an insight into the pathogenetic mechanisms underlying the inflammatory bowel diseases.
The case described below provides a further example of this association. The patient, currently 77 years old, had been a heavy smoker of up to 50 cigarettes/day from the age of 20, resulting in severe emphysema. There was no family history of bowel or hematologic disorders. During the investigation of osteoporotic vertebral crush fractures in August 1992, she was incidentally found to have thrombocytopenia and a peripheral blood monocytosis (2.0 × 10 9 /l). Examination of the bone marrow confirmed the diagnosis of chronic myelomonocytic leukemia (CMML) by FAB criteria, 5 revealing moderate hypercellularity, 9% monocytes and Ͻ1% blasts. Karyotype was diploid (46XX) in all 39 metaphases examined.
She received no specific therapy and remained asymptomatic, but was noted to have hepato-splenomegaly in October 1993. Her airways disease worsened, requiring frequent courses of corticosteroids from May 1994 onwards. By April 1997 she was symptomatic from progressive splenomegaly, but this promptly settled with the initiation of oral hydroxyurea. Following worsening of her osteoporosis and further painful vertebral crush fractures in October 1997, corticosteroids were weaned.
Concurrent with the withdrawal of corticosteroids, she developed watery diarrhea, abdominal pain, and weight loss and was found to have a serum albumin of 26 g/l and a markedly elevated CRP (134 mg/l; reference range 0-8 mg/l). Stool cultures were repeatedly negative, but imaging revealed marked thickening of the walls of the terminal ileum with mucosal ulceration. Although not evident to gross examination, endoscopic biopsies from the rectum and multiple sites throughout the colon revealed pathologic changes of ulcerative colitis including crypt abscesses. Her bowel symptoms improved following the commencement of mesalazine and the reintroduction of corticosteroids. As of March 1998, her CMML remains controlled with intermittent hydroxyurea.
As discussed by Hebbar et al 1 this patient was atypically elderly at the onset of her inflammatory bowel disease, although the steroid treatment of her pulmonary disease probably delayed the clinical manifestations. Unlike most reported cases, in this instance the diagnosis of MDS preceded the bowel disease (by 67 months). Although histologic features were consistent with ulcerative colitis, the terminal ileum was the dominant site of disease involvement; a distribution more typical of Crohn's disease. Consistent with the proposal of a common etiology, this patient had a long history of heavy cigarette use, although typical smoking-related karyotypic features were not present.
